The United Kingdom and the United States have reached a major bilateral deal that will maintain no tariffs on UK medicine products entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to raise spending on drugs through the public health system. This pledge ensures that tariffs on these crucial goods will stay at nothing for a period of three years.
This deal follows previous warnings to significantly raise import taxes on patented drug imports, with increases discussed up to 100%.
"This arrangement with the UK strengthens the global environment for new treatments and introduces much-needed balance to U.S.–U.K. pharmaceutical trade," a statement said.
Commercial Significance
Medicines constitute one of the the United Kingdom's largest goods shipped to the US, which is by far the biggest market for major British pharmaceutical firms.
Trade data indicate that in the year leading up to the third quarter, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This value represented 17.4% of all goods exports in that period.
"This agreement protects work, increases investment and sets the stage for the UK to emerge as a global hub for life sciences," a minister stated.
Specific NHS Changes
The pact entails several notable pledges from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, rebates exceeded twenty percent.
Industry Background
The pact takes place against a ongoing tension between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by arguments that US customers were charged a premium for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or cancelled, while major funding commitments have been announced toward American operations.
A senior figure stated that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the last ten years.
